RecruitingPhase 2NCT07600736

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy

A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric Participants With KCNT1-Related Epilepsy

Sponsor

Actio Biosciences, Inc.

Enrollment

45 participants

Start Date

May 18, 2026

Study Type

INTERVENTIONAL

Conditions

KCNT1-Related Epilepsy

Summary

This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy

Eligibility

Min Age: 1 MonthMax Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ABS-1230 and a drug called Placebo for people with kcnt1-related epilepsy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Month to 21 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGABS-1230

Once daily

DRUGPlacebo

Once daily

Locations(1)

Northeast Regional Epilepsy Group

Hackensack, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07600736

Related Trials

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

NCT071562011 location